You are here

Roche Products Pty Ltd

Active ingredients: 
tocilizumab (ACTEMRA)
Designation: 
Provisional determination
Effective Date: 
Monday, September 27, 2021
Lapse Date: 
Sunday, March 27, 2022
Designation Indication: 

For the treatment of coronavirus disease 2019 (COVID-19) (IV formulation only) in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.